Blog

Timeline of Major Advancements - From a protocol of 7 weeks to now 1 day Standard TMS In 2008, TMS was FDA-approved to treat major depressive disorder that did not resolve with antidepressants. The major clinical trial included 20-30 treatments, each of 38 minutes duration. It was sham-controlled and included...

Depression can negatively affect multiple facets of your life, leaving you feeling isolated and hopeless. For many, common anti-depressants and psychotherapy may not be enough to improve well-being. If you are struggling with depressive symptoms that do not respond to medications and traditional therapies, Spravato may be an effective alternative...

If you are currently taking or considering starting Spravato, you may have questions about the length of treatment. At The Neuropsychiatry & TMS Group, we are dedicated to helping you address your mental health concerns with open communication, in-depth guidance, and evidence-based treatment designed for your unique needs. If you...

Spravato treatment is a nasal spray used to treat persistent depression that has not responded to two or more oral antidepressants. By targeting different neural pathways in the brain, Spravato may help you find relief faster and more effectively than other therapies. Here, we will answer your questions, including those...

Spravato is a nasal spray containing esketamine. It has become a popular treatment option for many individuals experiencing persistent depression despite having tried multiple traditional antidepressants. If you are wondering how long Spravato treatment is, our knowledgeable providers at The Neuropsychiatry & TMS Group can answer your questions and help...

Learning Objectives  After reading this article, you should be able to: 1. Describe the mechanism of action of transcranial magnetic stimulation (TMS). 2. Explain the clinical considerations for determining a patient's suitability for TMS treatment. 3. Assess the comparative advantages of TMS over other treatment modalities, such as electroconvulsive therapy...

We are now offering the FDA-approved and insurance-covered treatment, Esketamine (Spravato), at The Neuropsychiatry and TMS Group. Esketamine is a molecule that is the mirror image of the better-known ketamine. Ketamine was initially FDA-approved as an anesthetic to be used during surgical procedures. In the early 2000s, it was studied...

Depression sufferers who can't take medication can use new technology that improves symptoms By: Wendy Ryan TAMPA, Fla. — Depression is often treated with medication, but a new technological advancement provides new hope for those who can't take antidepressants. "It's an FDA-approved treatment for depression. It was approved in 2008....

Transcranial Magnetic Stimulation (TMS) technology received FDA-approval in 2008 to treat depression patients whose symptoms are non-responsive to antidepressant medications. Historically, depression has been difficult to treat in about half of all diagnosed patients, marking TMS treatment as an extremely important development for the field of psychiatry. Let us imagine a new patient...

Program of Enhanced Psychiatric (PEP) Services for Patients with Brain Injury & Neuropsychiatric Disturbances (NPD): A Proposed Model of Care Faizi Ahmed, M.D., Kathleen Bechtold, Ph.D., Gwenn Smith, Ph.D., Durga Roy, M.D., Anita Everett, M.D., Vani Rao, M.D. Abstract Neuropsychiatric disturbances associated with brain injury occur frequently and are a...